JP2020518249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518249A5 JP2020518249A5 JP2019560107A JP2019560107A JP2020518249A5 JP 2020518249 A5 JP2020518249 A5 JP 2020518249A5 JP 2019560107 A JP2019560107 A JP 2019560107A JP 2019560107 A JP2019560107 A JP 2019560107A JP 2020518249 A5 JP2020518249 A5 JP 2020518249A5
- Authority
- JP
- Japan
- Prior art keywords
- subunit
- seq
- human interleukin
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims description 70
- 102000056374 human MYDGF Human genes 0.000 claims description 70
- 125000000539 amino acid group Chemical group 0.000 claims description 68
- 229920001184 polypeptide Polymers 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 235000018417 cysteine Nutrition 0.000 claims description 43
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 41
- 102000015696 Interleukins Human genes 0.000 claims description 36
- 108010063738 Interleukins Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 16
- 101100018698 Mus musculus Il27 gene Proteins 0.000 claims description 14
- 230000003248 secreting effect Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 7
- 230000001254 nonsecretory effect Effects 0.000 claims description 7
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 230000036303 septic shock Effects 0.000 claims description 6
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims description 5
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical group C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17169358.3 | 2017-05-04 | ||
| EP17169358 | 2017-05-04 | ||
| PCT/EP2018/061561 WO2018202876A1 (en) | 2017-05-04 | 2018-05-04 | Secretion-competent muteins of the human il-27 alpha-subunit |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518249A JP2020518249A (ja) | 2020-06-25 |
| JP2020518249A5 true JP2020518249A5 (https=) | 2021-06-17 |
| JP7249955B2 JP7249955B2 (ja) | 2023-03-31 |
Family
ID=58669684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560107A Active JP7249955B2 (ja) | 2017-05-04 | 2018-05-04 | ヒトＩＬ－２７のαサブユニットの分泌可能なムテイン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11358998B2 (https=) |
| EP (1) | EP3619228A1 (https=) |
| JP (1) | JP7249955B2 (https=) |
| CN (1) | CN110709413B (https=) |
| AU (1) | AU2018262811B2 (https=) |
| CA (1) | CA3060219A1 (https=) |
| WO (1) | WO2018202876A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| US20220380426A1 (en) * | 2019-11-12 | 2022-12-01 | Technische Universitat Mu | Homogeneous muteins of the human il-27 alpha-subunit |
| CN113307861A (zh) * | 2020-12-09 | 2021-08-27 | 重庆医科大学 | 细胞因子il-27作为nec与fpies鉴别诊断标志物及应用 |
| WO2024213695A1 (en) * | 2023-04-14 | 2024-10-17 | Technische Universitaet Muenchen | Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27 |
| CN116832146B (zh) * | 2023-06-30 | 2024-02-13 | 广东暨安特博生物科技有限公司 | Il-27蛋白在制备治疗阿尔茨海默症的产品的应用 |
| WO2025140436A1 (zh) * | 2023-12-27 | 2025-07-03 | 上海药明生物技术有限公司 | 重组il-27蛋白及其制备方法 |
| WO2025252853A1 (en) * | 2024-06-04 | 2025-12-11 | Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern | Fusion-polypeptide comprising a mutein of the alpha-subunit of human il-27 and at least one pharmaceutically acceptable fusion partner |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4839434B2 (ja) * | 2005-03-14 | 2011-12-21 | 千葉県 | ｐ２８分子またはその遺伝子を含む医薬製剤 |
| EP2831100A4 (en) * | 2012-03-26 | 2016-02-10 | Pronutria Inc | NUTRIENT PROTEINS AND METHOD |
-
2018
- 2018-05-04 CN CN201880029727.9A patent/CN110709413B/zh active Active
- 2018-05-04 AU AU2018262811A patent/AU2018262811B2/en active Active
- 2018-05-04 CA CA3060219A patent/CA3060219A1/en active Pending
- 2018-05-04 EP EP18726740.6A patent/EP3619228A1/en active Pending
- 2018-05-04 WO PCT/EP2018/061561 patent/WO2018202876A1/en not_active Ceased
- 2018-05-04 US US16/609,726 patent/US11358998B2/en active Active
- 2018-05-04 JP JP2019560107A patent/JP7249955B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518249A5 (https=) | ||
| JP2018171063A5 (https=) | ||
| JP2014510519A5 (https=) | ||
| CN102482324B (zh) | 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽 | |
| JP2018510622A5 (https=) | ||
| DK2633865T3 (en) | USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS | |
| JP2013542715A5 (https=) | ||
| JP2011502479A5 (https=) | ||
| JP2013513377A5 (https=) | ||
| JP2018524299A (ja) | 免疫応答を調節するための方法およびポリペプチド | |
| IL278418B2 (en) | Vaccine composition | |
| JP2016519569A5 (https=) | ||
| ES2700149T3 (es) | Proteínas de fusión de UTI | |
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| TW201629085A (zh) | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 | |
| JP2006506942A5 (https=) | ||
| JP2018506287A5 (https=) | ||
| JP2007535910A5 (https=) | ||
| JP2026035742A (ja) | 生体高分子標的特異的補体阻害剤及びその製造方法と応用 | |
| CN108727486A (zh) | 长效神经生长因子、制备方法及其组合物 | |
| CN1316431A (zh) | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 | |
| JPWO2021021606A5 (https=) | ||
| RU2010141916A (ru) | Растворимый мутант рецептора фактора некроза опухоли | |
| WO2019228032A1 (zh) | 磷酸化多肽抗原疫苗及其制备方法和应用 | |
| JP2013535965A5 (https=) |